|Mr. Randy D. Milby MBA||Pres, Chairman & CEO||471.94k||N/A||1954|
|Mr. Sireesh Appajosyula Pharm.D.||COO & Director||64.96k||N/A||1976|
|Mr. Thomas P. Hess CPA, MBA||Chief Financial Officer||N/A||N/A||1964|
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
Hillstream BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.